Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice

Beatriz Aviles Bueno; Maria Jose Soler; Luis Perez-Belmonte; Anabel Jimenez Millan; Francisco Rivas Ruiz; Maria Dolores Garcia de Lucas

doi:10.1093/ckj/sfac096

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice

Clin Kidney J. 2022 Apr 11;15(8):1593-1600. doi: 10.1093/ckj/sfac096. eCollection 2022 Aug.

Authors

Beatriz Aviles Bueno¹, Maria Jose Soler², Luis Perez-Belmonte³, Anabel Jimenez Millan⁴, Francisco Rivas Ruiz⁵, Maria Dolores Garcia de Lucas⁶

Affiliations

¹ Costa del Sol Hospital, Nephrology Department, Málaga, Spain.
² Vall D´Hebron University Hospital, Nephrology Department, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Regional University Hospital and Biomedical Research Institute, Internal Medicine Department Málaga, Spain.
⁴ Puerto Real University Hospital, Endocrinology Department, Cádiz, Spain.
⁵ Costa del Sol Hospital, Internal Medicine Department, Málaga, Spain.
⁶ Research Unit, Marbella, Málaga, Spain.

Abstract

Background: Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have been rarely studied.

Methods: This is a multicenter, retrospective, observational study in patients with T2D and CKD with glycosylated hemoglobin A1c (HbA1c) of 7.5-9.5% treated with subcutaneous semaglutide for 12 months in real-world clinical practice. The main objectives were glycemic control as HbA1c <7% and weight loss >5%.

Results: We studied a total of 122 patients, ages 65.50 ± 11 years, 62% men, duration of T2D 12 years, baseline HbA1c 7.57% ± 1.36% and an estimated glomerular filtration rate (eGFR) 50.32 ± 19.21 mL/min/1.73 m²; 54% had a urinary albumin:creatinine ratio (UACR) of 30-300 mg/g and 20% had a UACR >300 mg/g. After 12 months of follow-up, HbA1c declined -0.73% ± 1.09% (P < .001), with 57% of patients achieving values <7% and weight loss of -6.95 kg (P < .001), with 59% of patients showing a reduction of >5% of their body weight. Systolic and diastolic blood pressure decreased -9.85 mmHg and -5.92 mmHg, respectively (P < .001). The mean UACR decreased 51% in the group with baseline macroalbuminuria (UACR >300 mg/g). The mean eGFR (by the Chronic Kidney Disease Epidemiology Collaboration) remained stable. The need for basal insulin decreased 20% (P < .005). Only 7% of patients on insulin had mild hypoglycemic episodes. Semaglutide was stopped in 5.7% of patients for digestive intolerance.

Conclusions: In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by >50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.

Keywords: GLP-1RA; albuminuria; diabetic chronic disease; obesity; semaglutide.